Morgan Stanley Downgrades Neogenomics (NEO) to Equalweight, Following Earnings
Tweet Send to a Friend
Morgan Stanley analyst Tejas Savant downgraded Neogenomics (NASDAQ: NEO) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
